Edelson Lechtzin Initiates Investigation into Arcturus Therapeutics

Edelson Lechtzin LLP has announced an investigation into potential violations of federal securities laws involving Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT). The inquiry stems from allegations that the company may have provided misleading business information to investors, raising concerns about the accuracy of its public statements.

The investigation was prompted by the release of Phase 2 trial results on October 22, 2025, for Arcturus’s inhaled mRNA therapy, ARCT-032, aimed at treating cystic fibrosis. The trial results indicated no significant improvement in lung function, specifically FEV1, leading to a drastic decline in the company’s stock price. Following the announcement, shares plummeted by 50.17%, closing at $11.54 per share.

Edelson Lechtzin LLP is actively encouraging investors who may have suffered substantial losses in connection with Arcturus to reach out. The firm is seeking non-public information that could aid in its investigation. Interested parties can contact Eric Lechtzin, an attorney at the firm, via telephone at 844-563-5550 or through email at [email protected].

About Arcturus Therapeutics

Arcturus specializes in developing innovative mRNA vaccines and therapies. The company’s focus on this cutting-edge technology positions it at the forefront of advancements in the biotechnology sector. Despite its ambition and potential, the recent trial results have raised questions about its product efficacy and future growth prospects.

The investigation by Edelson Lechtzin LLP highlights the firm’s commitment to addressing potential securities violations, particularly in the context of investor protection. The firm has a notable background in pursuing class action lawsuits related to securities and investment fraud.

Edelson Lechtzin LLP Overview

Based in Newtown, Pennsylvania, with additional offices in California, Edelson Lechtzin LLP is a prominent national class action law firm. Its practice areas extend beyond securities and investment fraud, encompassing cases related to federal antitrust laws, violations of fiduciary duties under ERISA, wage theft, consumer fraud, and issues surrounding dangerous medical products.

For further information regarding the investigation or to discuss potential claims, investors are encouraged to reach out to the firm’s legal representatives. The firm emphasizes that no class action has been certified at this stage, meaning investors are not currently represented unless they choose to retain counsel.

The ongoing investigation serves as a reminder of the importance of corporate transparency and accountability, particularly in industries where public health and safety are at stake. As developments unfold, stakeholders will be closely monitoring Arcturus’s response and the implications for investors affected by the recent downturn.